Research ArticleArticle
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies
Yue Chen, Nelamangala V. Nagaraja, Bin Fan, Luke Utley, Rene M. Lemieux, Janeta Popovici-Muller, Lenny Dang, Hyeryun Kim, Liping Yan, Shin-San M. Su, Scott A. Biller and Hua Yang
Drug Metabolism and Disposition October 2021, 49 (10) 870-881; DOI: https://doi.org/10.1124/dmd.120.000234
Yue Chen
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Nelamangala V. Nagaraja
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Bin Fan
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Luke Utley
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Rene M. Lemieux
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Janeta Popovici-Muller
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Lenny Dang
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Hyeryun Kim
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Liping Yan
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Shin-San M. Su
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Scott A. Biller
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)
Hua Yang
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)

DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Preclinical Drug Metabolism and PK Profile of Ivosidenib
Yue Chen, Nelamangala V. Nagaraja, Bin Fan, Luke Utley, Rene M. Lemieux, Janeta Popovici-Muller, Lenny Dang, Hyeryun Kim, Liping Yan, Shin-San M. Su, Scott A. Biller and Hua Yang
Drug Metabolism and Disposition October 1, 2021, 49 (10) 870-881; DOI: https://doi.org/10.1124/dmd.120.000234
Research ArticleArticle
Preclinical Drug Metabolism and PK Profile of Ivosidenib
Yue Chen, Nelamangala V. Nagaraja, Bin Fan, Luke Utley, Rene M. Lemieux, Janeta Popovici-Muller, Lenny Dang, Hyeryun Kim, Liping Yan, Shin-San M. Su, Scott A. Biller and Hua Yang
Drug Metabolism and Disposition October 1, 2021, 49 (10) 870-881; DOI: https://doi.org/10.1124/dmd.120.000234
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement